Core Insights - Tactile Systems Technology, Inc. presented new six-month clinical data showing sustained benefits of Flexitouch® Plus for treating lymphedema in head and neck cancer patients [1][2] Clinical Data Summary - The six-month analysis from a large randomized controlled trial indicated improvements in lymphedema symptom burden for participants using Flexitouch Plus compared to usual care [2] - Significant reductions in internal swelling were observed at 13 out of 19 anatomical sites, with notable improvements in the base of tongue (p=0.008) and arytenoids (p=0.023) [6] - Both treatment groups maintained initial patient benefits over the six-month study period, demonstrating sustained improvement in symptom burden [6] Expert Commentary - The Principal Investigator highlighted the importance of the findings, noting that up to 90% of head and neck cancer survivors develop lymphedema within a year of treatment, with many experiencing moderate to severe fibrosis [3] - The CEO of Tactile Medical emphasized the need for broader dissemination of study results to inform clinical guidelines and improve access to Flexitouch Plus for patients [4] Company Overview - Tactile Medical focuses on developing at-home therapies for chronic conditions, aiming to improve patient quality of life and reduce healthcare costs [5]